Global Alopecia Treatment Market - 2022-2029

Market Overview

Alopecia Treatment Market was valued US$ 8.24 billion in 2021 and is estimated to reach US$ 14.8 billion by 2029, growing at a CAGR of 8.0% during the forecast period (2022-2029).

Alopecia is the partial or complete loss of hair, especially on the scalp, entire head, or the entire body. It is classified into different types as the alopecia areata, androgenic alopecia, alopecia totalis, traction alopecia, alopecia Universalis, and cicatricial alopecia. It occurred due to heredity, hormonal changes, medical conditions, or a normal part of aging. Drugs, hair transplants, and laser therapy are used for the treatment of Alopecia.

Market Dynamics

The alopecia treatment market is driven by the growing prevalence of chronic diseases, such as acute stress disorder, polycystic ovary disease (pcod), hyperthyroidism, hypothyroidism, cancer, lupus, and hypopituitarism.

Increasing prevalence of alopecia and rising R&D activities for alopecia therapy are expected to drive market growth

The market is driven by the increasing demand for alopecia treatment with the increasing prevalence of alopecia due to the increasing consumption of tobacco and alcohol. Several factors, such as aging and hormonal anomalies, lead to the development of Alopecia. The growing prevalence of chronic diseases, such as acute stress disorder, Polycystic Ovary Disease (PCOD), hyperthyroidism, hypothyroidism, cancer, lupus, and hypopituitarism, shall stimulate market growth.

There is increasing research and development activities for the development of Alopecia therapies. The expected approval of emerging therapies shall stimulate market growth. For instance, in July 2020, Concert Pharmaceuticals, Inc. had received the Breakthrough Therapy Designation for the oral Janus kinase inhibitor, CTP-543, to treat adult patients with moderate-to-severe alopecia areata. The clinical trial has demonstrated that the use of the CTP-543 among patients with moderate-to-severe alopecia areata. The patients were treated with either 8 mg twice-daily or 12 mg twice-daily of CTP-543. CTP-543 has met the primary efficacy endpoint with statistically significant differences relative to placebo in the patients achieving a ≥ 50% relative change from baseline at 24 weeks as measured by the Severity of Alopecia Tool (SALT). CTP-543 was generally well tolerated. Only one serious adverse event was reported among the patients.

In March 2020, Eli Lilly had received the breakthrough therapy designation from the United Food and Drug Administration (FDA) for baricitinib to treat alopecia areata. Baricitinib is the once-daily oral JAK inhibitor. The Phase II trial of the baricitinib conducted among the patients with the alopecia areata demonstrated no new safety signals with no serious adverse events. Only mild or moderate treatment-emergent adverse events (TEAEs) were observed among the patients.

Several organizations, associations, and institutes are involved in researching the management and treatment of alopecia. For instance, The National Alopecia Areata Foundation (NAAF) is a non-profit organization involved in raising awareness regarding the alopecia areata. NAAF supports research to find a cure or acceptable treatment for alopecia areata, supports those with the disease, and educates the public about alopecia areata. This organization provides support, awareness & advocacy, and research to find a treatment or cure for alopecia.

Minor & Major side effects of drugs is likely to hinder the market growth

According to the US Pharmacist, a clinically-focused pharmacy publication, published an article- Treatment Options for Androgenetic Alopecia, in 2020 that medication used for the treatment of androgenetic alopecia has many side effects. For example, topical minoxidil can cause local erythema and pruritus and also some side effects like Edema (swelling), excessive hair growth on face, hair discoloration, tachycardia, breast pain. Oral drug finasteride can cause dizziness, orthostatic hypotension and others. These are the major restricting factors of the market growth.

Industry Analysis

The global alopecia treatment market provides in-depth analysis of the market based on various industry factors such as porter's five forces, regulatory analysis, supply chain analysis and pricing analysis, reimbursement analysis, unmet needs.

Segment Analysis

Alopecia areata segment is expected to hold the largest market share in global alopecia treatment market

The alopecia areata segment accounts for the highest market due to the high prevalence of alopecia areata. According to the National Alopecia Areata, approximately 147 million people are affected by alopecia areata worldwide. Alopecia areata is presented with discrete, smooth patches of alopecia on the scalp. It also occurs in other hair-bearing areas, such as the eyebrows, eyelashes, beard, and extremities. Alopecia areata is prevalent among patients with autoimmune diseases, i.e., Down's syndrome, diabetes, and hyperthyroidism. It can progress into the alopecia Universalis and totalis. Several companies are focusing on developing therapies for the treatment of Alopecia Areata. There is the presence of a promising pipeline for the treatment of Alopecia Areata. For instance, in January 2019, Pfizer Inc. had initiated the Phase II/III trial of oral JAK3 inhibitor, PF-06651600, to treat patients with moderate to severe alopecia areata.

Geographical Analysis

North America region holds the largest market share in the global alopecia treatment market

North America dominated the alopecia treatment market due to the high prevalence of alopecia. According to the National Alopecia Areata, approximately 6.8 million people are affected by alopecia areata in the United States. According to the American Hair Loss Association, approximately 95% of hair loss occurred due to androgenetic alopecia among men. Several public and private companies raise the investment for the research and development activities for the novel therapies to treat alopecia. There is growing innovation for the development of therapies for the treatment of alopecia. The high prevalence of acute stress disorder, polycystic ovary disease (pcod), hyperthyroidism, hypothyroidism, cancer, lupus, and hypopituitarism shall stimulate market growth.

Competitive Landscape

The alopecia treatment market is highly competitive with the presence of several international and local market players. Disease diversification, technological advancement, revenue generation, and opportunities intensify the market competition. Aclaris Therapeutics Inc., Cipla Inc., Concert Pharmaceuticals Inc., Daiichi Sankyo Inc., GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co. Inc., and Sun Pharmaceuticals Industries Ltd are the leading market players with significant market share.

Companies are using product development, research and development, technology advancement, and market expansion strategies for holding their position in the market. For instance, in June 2020, Follica, Inc. had received positive feedback from a meeting with the U.S. Food and Drug Administration (FDA) as the company prepares to advance its lead program into Phase III development following a successful safety and efficacy optimization study for the treatment of hair loss in male androgenetic alopecia.

• In December 2019, Follica, Inc. had announced the topline results from its safety and efficacy optimization study to treat hair loss in male androgenetic alopecia. The study was designed to select the optimal treatment regimen using Follica's proprietary device combined with a topical drug and successfully met its primary endpoint. The treatment regimen demonstrated a statistically significant 44% improvement of visible hair count after three months of treatment compared to baseline. The overall improvement of visible hair count after three months of treatment was 29% compared to baseline, and a substantially improved outcome was seen with the optimal treatment regimen.
• In Aug 2021, Aclaris Therapeutics, Inc. a clinical-stage biopharma company that develops new drug candidates for immuno-inflammatory diseases, announced its non-exclusive patent license agreement with Eli Lilly and Company by which Aclaris gave some rights to Lilly under patents that Aclaris licences for usage of JAK inhibitor of Lilly baricitinib for Alopecia areata treatment.

Key Companies to Watch

Aclaris therapeutics Inc:

Overview: Aclaris therapeutics is clinical stage biopharma company that develops novel dermatological therapies and pipeline of drugs for immune-inflammatory diseases. It was founded in 2009 and is headquartered in Pennsylvania, United States.

Product Portfolio:

XELJANZ: It is the oral medicine that can be prescribes off label for alopecia areata treatment. It is also known as Tofacitinib. It is not FDA approved medicine for hair loss.

Key Developments: In Aug 2022, Aclaris announced its patent licence agreement for alopecia areata with Lilly.

The global alopecia treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.